Abrocitinib: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01638-3
Abstract: Abrocitinib (Cibinqo®) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In September 2021, abrocitinib was approved in the UK and Japan… read more here.
Keywords: first approval; treatment moderate; abrocitinib; moderate severe ... See more keywords
An evaluation of abrocitinib for moderate-to-severe atopic dermatitis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2126353
Abstract: ABSTRACT Introduction Atopic dermatitis (AD) is a common itchy inflammatory skin condition that affects many individuals. For many years, the landscape of AD treatment remained unchanged; however, there has been developing therapies that directly target… read more here.
Keywords: atopic dermatitis; evaluation abrocitinib; moderate severe; abrocitinib ... See more keywords
Upadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate-to-Severe Atopic Dermatitis: An Updated Meta-Analysis
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1155/2023/9067797
Abstract: Background. Blocking agent for immune cytokine pathways is a novel treatment for atopic dermatitis (AD). Janus kinase (JAK) family is one of the cytoplasmic tyrosine kinases that mediate a variety of cytokines. Eight randomized controlled… read more here.
Keywords: moderate severe; abrocitinib; jak1 inhibitors; atopic dermatitis ... See more keywords
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15020385
Abstract: Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and… read more here.
Keywords: atopic dermatitis; efficacy safety; abrocitinib; jak1 ... See more keywords